Does TREPROSTINIL Cause Product packaging quantity issue? 18 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 18 reports of Product packaging quantity issue have been filed in association with TREPROSTINIL (TYVASO). This represents 0.0% of all adverse event reports for TREPROSTINIL.
18
Reports of Product packaging quantity issue with TREPROSTINIL
0.0%
of all TREPROSTINIL reports
0
Deaths
6
Hospitalizations
How Dangerous Is Product packaging quantity issue From TREPROSTINIL?
Of the 18 reports, 6 (33.3%) required hospitalization.
Is Product packaging quantity issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TREPROSTINIL. However, 18 reports have been filed with the FAERS database.
What Other Side Effects Does TREPROSTINIL Cause?
Dyspnoea (16,348)
Headache (14,051)
Diarrhoea (11,335)
Nausea (10,320)
Cough (8,945)
Fatigue (7,440)
Dizziness (7,405)
Infusion site pain (5,169)
Vomiting (5,097)
Death (4,764)
What Other Drugs Cause Product packaging quantity issue?
LEUPROLIDE (523)
ALBUTEROL (431)
BUDESONIDE\FORMOTEROL (301)
FENTANYL (286)
BUPRENORPHINE (225)
CYCLOSPORINE (206)
ESTRADIOL (201)
BIMATOPROST (177)
RIVAROXABAN (174)
EXENATIDE (154)
Which TREPROSTINIL Alternatives Have Lower Product packaging quantity issue Risk?
TREPROSTINIL vs TREPROSTINIL DIOLAMINE
TREPROSTINIL vs TRETINOIN
TREPROSTINIL vs TRIAMCINOLONE
TREPROSTINIL vs TRIAMCINOLONE ACETONIDE
TREPROSTINIL vs TRIAMCINOLONE HEXACETONIDE